Monitor for future Form 4 filings to see if any new inducement grants are made under this expanded plan. The increased share reserve provides flexibility for hiring, but does not represent immediate dilution.
XENE drugs
XENE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 14 $59.35entry
- T+1 · 7mo ago −0.79%α −1.57% · $58.88
- T+5 · 7mo ago −4.97%α −6.36% · $56.40
- T+20 · 6mo ago −6.02%α −12.31% · $55.78
- T+60 · 4mo ago +19.56%α +11.04% · $70.96
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Xenon Pharmaceuticals amended and restated its 2025 Inducement Equity Incentive Plan to increase the share reserve from 900,000 to 1,175,000 common shares, to be used exclusively for hiring inducements. This filing is routine and does not involve any new equity grants or executive appointments.
Key Facts
- Company amended and restated its 2025 Inducement Equity Incentive Plan
- Increased share reserve from 900,000 to 1,175,000 common shares
- New shares to be used exclusively for inducement grants to new hires or rehires
- No shareholder approval required under Nasdaq Listing Rule 5635(c)(4)
- Filing is administrative and does not involve any new equity grants
Financial Impact
Potential future dilution of up to 1,175,000 shares, but no immediate financial impact as no new grants were issued
Risk Factors
- Potential future dilution if the full share reserve is utilized
- No immediate risk as no new grants were issued in this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-152834 |
| Document: xene-20260407.htm | 0001193125-26-152834 |
| Document: 0001193125-26-152834-index-headers.html | 0001193125-26-152834 |
| Document: 0001193125-26-152834-index.html | 0001193125-26-152834 |
| Document: 0001193125-26-152834.txt | 0001193125-26-152834 |
Track record
19 reports on XENE
3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
- Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
- Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
- Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers